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Abstracts

RADI-11. EVALUATING THE TISSUE EFFECTS OF DOSEESCALATED PRE-OPERATIVE STEREOTACTIC RADIOTHERAPY
FOR RESECTABLE BRAIN METASTASIS
Rupesh Kotecha1,2, Raees Tonse1, Miguel A. Ramirez Menendez3,
Andre Williams3, Zuanel Diaz3, Martin C. Tom1,2, Matthew D. Hall1,2,
Minesh P. Mehta1,2, Vitaly Siomin4,2, Manmeet S. Ahluwalia5,2,
Michael W. McDermott4,2; 1Department of Radiation Oncology, Miami
Cancer Institute, Baptist Health South Florida, Miami, FL, USA, 2Herbert
Wertheim College of Medicine, Florida International University, Miami, FL,
USA, 3Office of Clinical Research, Miami Cancer Institute, Baptist Health
South Florida, Miami, FL, USA, 4Department of Neurosurgery, Miami
Neuroscience Institute, Baptist Health South Florida, Miami, FL, USA,
5Department of Medical Oncology, Miami Cancer Institute, Baptist Health
South Florida, Miami, FL, USA
BACKGROUND: Although the classic radiobiologic principles of radiotherapy are well understood, the unique effects of the large fractional does that
characterize stereotactic radiotherapy (SRT), specifically in terms of antitumor
immune cellular processes, vascular damage, tumor necrosis, and apoptosis
on brain metastasis have yet to be adequately demonstrated. The objective of
this study is to provide the first in-human evaluation of the biological effects
of SRT in resected brain metastasis. METHODS: All paired primary tumors
and metastases for patients who underwent dose-escalated preoperative SRT
followed by resection were evaluated for tumor necrosis using hematoxylineosin staining. T cells (CD3+, CD4+, CD8+), natural killer cells (CD56+),
vessel density (CD31+), and apoptotic factors (caspase-3) were determined by
immunohistochemical analysis. RESULTS: Fifteen patients with brain metastases from solid tumors received a median preoperative SRT dose of 18 Gy
(range: 15–18 Gy) in 1 fraction, with 2 patients receiving 27–30 Gy in 3–5
fractions, followed by resection within a median interval of 90 hours (Range:
17.1–260 hours). The rate of necrosis was found to be significantly higher
in irradiated brain metastases than in non-irradiated primary tumor samples (mean paired difference: 30.47, SD: 29.28, p=0.001). A decrease in all
immunomodulatory cell populations was found in irradiated metastasis: CD3
(mean paired difference -19.4, SD: 31.7, p=0.03), CD4 (-10.0, SD: 20, p=0.01),
and CD8 (-17.4, SD: 22.1, p=0.008). While irradiated samples had numerically
lower CD 31+, CD 56+, and caspase-3 scores, the difference was not statistically
significant. Time interval from SRT to surgery had no effect on these parameters. CONCLUSIONS: There is complex interplay between tumor-associated
cells and the unique radiobiological effects of SRT on tumor tissue. Although
time interval from SRT to surgery was associated with increased tumor necrosis,
differences in immunomodulatory factors may be multifactorial, including concurrent corticosteroids or the immunosuppressive effect of SRT.

radiosurgery (SRS). VBrain is a deep learning algorithm, recently FDA-cleared,
to assist in brain tumor contouring. In this study, we aimed to further validate
this tool in patients treated with SRS for brain metastases at Stanford Cancer
Center. METHODS: We included randomly selected patients with brain metastases treated with SRS from 2008 to 2020. Computed tomography (CT)
and axial T1-weighted post-contrast magnetic resonance (MR) image data
were extracted for each patient and uploaded to VBrain. Subsequent analyses compared the output contours from VBrain with the physician-defined
contours used for SRS. A brain metastasis was considered “detected” when
the VBrain “predicted” contours overlapped with the corresponding physician contours (“ground-truth” contours). We evaluated performance against
ground-truth contours using the following metrics: lesion-wise Dice similarity
coefficient (DSC), lesion-wise average Hausdorff distance (AVD), false positive count (FP), and lesion-wise sensitivity (%). RESULTS: We analyzed 60
patients with 321 intact brain metastases treated over 70 SRS courses. Resection cavities were excluded from the analysis. The median (range) tumor size
was 132 mm3 (7 to 24,765). Input CT scan slice thickness was 1.250 mm,
and median (range) pixel resolution was 0.547 mm (0.457 to 0.977). Input
MR scan median (range) slice thickness was 1.000 mm (0.940 to 2.000),
and median (range) pixel resolution was 0.469 mm (0.469 to 1.094). In assessing VBrain performance, we found mean lesion-wise DSC to be 0.70,
mean lesion-wise AVD to be 9.40% of lesion size (0.805 mm), mean FP to be
0.657 tumors per case, and lesion-wise sensitivity to be 84.5%. CONCLUSION: Retrospective analysis of our brain metastases cohort using a deep
learning algorithm yielded promising results. Integration of VBrain into the
clinical workflow can provide further clinical and research insights.
RADI-13. SYSTEMIC THERAPY TYPE AND TIMING EFFECTS
ON RADIATION NECROSIS RISK IN HER2+ BREAST CANCER
BRAIN METASTASES PATIENTS TREATED WITH STEREOTACTIC
RADIOSURGERY
Christine Park, Evan Buckley, Amanda Van Swearingen, Will Giles,
James Herndon, Scott Floyd, Carey Anders; Duke University, Durham, NC,
USA
BACKGROUND: Current standard of care options for HER2+ breast
cancer brain metastasis (BCBrM) include radiation therapy, brain permeable
systemic therapies, and in select cases, neurosurgical resection. There is a
concern that HER2-directed systemic therapies when administered concurrently with stereotactic radiosurgery (SRS) may increase the risk of radiation
necrosis (RN). This study explores the impact of timing and type of systemic
therapies on the development of RN in patients treated with SRS for HER2+
BCBrM. METHODS: This was a single-institution, retrospective study
including patients ≥18 years of age with HER2+ BCBrM who received SRS
between 2013 and 2018 with at least 12-month post-SRS follow-up. Presence
of RN was determined at one-year post-SRS. Demographics, radiotherapy
parameters, and timing (“during” defined as four weeks before/after SRS)
and type of systemic therapy were evaluated. RESULTS: Among 46 patients
with HER2+ BCBrM who received SRS, 28 (60.9%) developed RN and 18
(39.1%) did not. Age (mean 53.3 vs 50.4 years, respectively), radiotherapy
parameters (dose, fraction, CTV, GTV, CI, V12Gy, all p>0.05), and receipt
of any type of systemic therapy during SRS (60.7% vs 55.6%, p = 0.97)
did not differ between patients who did or did not develop RN. However,
patients who developed RN more commonly received more than one line
of HER2-directed therapy independent of SRS timing compared to those
who did not develop RN (75.0% vs 44.4%, p = 0.08). In fact, a significantly
higher proportion of those who developed RN received more than one line
of HER2-directed therapy during a given SRS treatment compared to those
did not develop RN (35.7% vs 5.6%, p<0.05). CONCLUSIONS: Patients
with HER2+ BCBrM who receive multiple lines of HER2-directed therapy
during SRS for BCBrM may be at higher risk of RN. Collectively, this data
supports a practice of holding HER2-directed therapy during treatment with
SRS if medically acceptable.

RADI-14. BEVACIZUMAB VS LASER INTERSTITIAL THERMAL
THERAPY IN RADIATION NECROSIS FROM BRAIN METASTASES:
A SYSTEMATIC REVIEW AND META-ANALYSIS

Jen-Yeu Wang1, Navjot Sandhu1, Maria Mendoza1, Jhih-Yuan Lin2,
Yueh-Hung Cheng2, Yu-Cheng Chang2, Chih-Hung Liang2,
Jen-Tang Lu2, Scott Soltys1, Erqi Pollom1; 1Department of Radiation
Oncology, Stanford University School of Medicine, Palo Alto, CA, USA,
2Vysioneer Inc, Cambridge, MA, USA

Paolo Palmisciano1, Ali S. Haider2, Chibueze D. Nwagwu3,
Waseem Wahood4, Navraj S. Sagoo5, Salah G. Aoun6, Kalil G. Abdullah6,
Tarek Y. El Ahmadieh6; 1Department of Neurosurgery, Trauma, Gamma
Knife Center, Cannizzaro Hospital, Catania, Italy, 2Texas A&M University
College of Medicine, Houston, TX, USA, 3Emory University School of
Medicine, Atlanta, GA, USA, 4Dr. Kiran C. Patel College of Allopathic
Medicine, Nova Southeastern University, Davie, FL, USA, 5University
of Texas Medical Branch School of Medicine, Galveston, TX, USA,
6Department of Neurological Surgery, University of Texas Southwestern
Medical Center, Dallas, TX, USA

INTRODUCTION: Artificial intelligence-based tools can significantly
impact detection and segmentation of brain metastases for stereotactic

OBJECTIVE: Radiation necrosis (RN) represents a serious postradiotherapy complication in patients with brain metastases. Bevacizumab

RADI-12. DEEP LEARNING FOR AUTOMATIC DETECTION
AND CONTOURING OF METASTATIC BRAIN TUMORS IN
STEREOTACTIC RADIOSURGERY: A RETROSPECTIVE ANALYSIS
WITH AN FDA-CLEARED SOFTWARE ALGORITHM
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sible detriment in cognition post-radiation. We sought to compare the efficacy
and safety between the surgical resection of brain metastases (BM) plus radiotherapy versus surgical resection alone. MATERIALS AND METHODS: We
searched various biomedical databases from 1983 to 2019, for eligible randomized controlled trials (RCT). Outcomes studied were local recurrence (LR),
overall survival (OS), and serious (Grade 3 +) adverse events (AE). We used the
random-effects model to pool outcomes. The methodological quality of each
study was assessed using the Cochrane Risk of Bias tool. RESULTS: We included 5 RCTs comprising of 673 patients. The odds ratio (OR) for LR ranged
from 0.06–0.34 with a pooled odds ratio of 0.26 (95% confidence interval (CI)
0.19–0.37, P< 0.001), strongly favoring the patients who received postoperative
radiation. The overall survival (OS) was only reported in 3 studies and did not
show any significant difference. The hazard ratio (HR) ranged from 1.01–1.29
with a pooled HR of 1.1 (95% CI 0.90–1.34, P=0.37). The treatment-related
toxicities were inconsistently reported to draw any meaningful conclusions.
The risk of bias was predominantly due to the lack of blinding and was deemed
to be high, affecting all outcomes. CONCLUSION: Our analysis confirms that
postoperative radiation should be recommended after surgical resection of BM,
for it significantly reduces the risk of local recurrence. However, we did not
find any improvement in OS, suggesting that improvements in local control
at the tumor bed alone may not impact survival. Balancing local control, and
possible neuro-cognitive effects of whole-brain radiation, post-operative cavity
radiation seems to be an attractive option.

Abstracts

among the four subtypes of MBC. RESULTS: 39% of the patients belonged
to Luminal A, 25%, 22% and 14% belonged to Luminal B, Her2 amplified
and Basal respectively. Patients under Luminal A, presented with brain metastases by 25 months after the diagnosis of the primary. 60% presented with
single lesion, amenable to resection and 58% underwent surgery followed by
WBRT and OS fared better as compared to patients with WBRT alone with
no distant recurrences on imaging and improvement in KPS. Patients with
Luminal B/ HER2 amplified subgroup had predominantly oligometastatic
lesions (65%), presented with brain metastases at 15 months after diagnosis of Carcinoma Breast,18% received Herceptin and Lapatinib and 33%
and 22% received Herceptin and Lapatinib alone. OS was superior over
WBRT alone with exaggerated radiation necrosis in those who took concurrent biological therapy and RT.In patients with Basal subtype,75%had
multiple metastatic brain lesions, presented with symptoms by 10 months
of diagnosis of the primary with poor KPS and OS remained poor despite
WBRT. CONCLUSIONS: Lesions being amenable for surgery, focal RT to
post op cavity alone may be considered in patients with Luminal A. WBRT
plus boost for those unfit for surgery. Addition of TKI +/- oral chemo for all
patients with Luminal B and HER 2 amplified to Focal RT or WBRT. Triple
Negative patients present with poor KPS can be considered for BSC/WBRT
on case basis.

RADI-15. RADIOTHERANOSTIC APPROACH IN BRAIN TUMOR

Ran An1, Yan Wang1, Fuchenchu Wang2, Akshara Singareeka
Raghavendra3, Chao Gao4, Diana N. Amaya1, Nuhad K. Ibrahim3,
Jing Li1; 1MD Anderson Cancer Center, The University of Texas, Radiation
Oncology, Houston, TX, USA, 2MD Anderson Cancer Center, The
University of Texas, Biostatistics, Houston, TX, USA, 3MD Anderson
Cancer Center, The University of Texas, Breast Medical Oncology,
Houston, TX, USA, 4The Fourth Hospital of Hebei Medica University,
Shijiazhuang, China

Reza Nemati1, Seyed Javad Rekabpour2, Narges Jokar3,
Hojjat Ahmadzadehfar4, Hossein Shooli3, Esmail Jafari3, Majid Assadi3;
1Department of Neurology, Bushehr Medical University Hospital,
Bushehr University of Medical Sciences, Bushehr, Iran, Islamic Republic
of, 2Department of Oncology, Bushehr Medical University Hospital,
Bushehr University of Medical Sciences, School of Medicine, Bushehr, Iran,
Islamic Republic of, 3The Persian Gulf Nuclear Medicine Research Center,
Department of Molecular Imaging and Radionuclide Therapy (MIRT),
Bushehr Medical University Hospital, Bushehr University of Medical
Sciences, Bushehr, Iran, Islamic Republic of, 4Department of Nuclear
Medicine, Klinikum Westfalen, Dortmund, Germany, Dortmund, Germany
PURPOSE: The aim of this study is feasibility and potential treatment of
targeted radionuclide theranostic approach for patients with brain tumors.
METHODS: For the period 2020–2021, 6 child and adult patients who had
been diagnosed with brain tumors were treated using theranostic approach
followed by refractory to conventional therapy. Two patients that were presented with HER-2 positive, ER and PR negative breast cancer and brain
metastases as well as a history of several cycles of chemotherapy sessions
and radiotherapy using gamma knife were treated with 177Lu-Trastuzumab
(Herceptin). Three other patients with primary brain tumor underwent peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. The last
case was a patient with refractory primary cerebral lymphoma to standard
therapy with confirmed CD20-positive B-cell lymphoma who underwent
177Lu-Rituximab. RESULTS: A two women with HER-2 positive breast
cancer and brain metastasis underwent two cycles of 177Lu-trastuzumab.
Post-therapy assessment showed some improvement. Next, a man with a
high-grade glioma tumor in the left frontal lobe with history of debunking
surgery in combination with chemoradiation received 177Lu-DOTATATE
that resulted in a short-term stable situation. Another patient presented
with a right cerebellopontine angle meningioma underwent PRRT with
177Lu-DOTATATE. She had a stable disease with some improvement in
the clinical status. Also, a girl with an astrocytoma in suprasellar cistern
underwent 2 cycles of 177Lu-DOTATATE. The complete response was designed. Finally, a patient with refractory primary cerebral lymphoma received 177Lu-Rituximab. CONCLUSION: Nuclear oncology in the field
of neuro-oncology (neuroradiotheranostics) has been toward a personalized
approach, effective and safe therapy. These preliminary studies might demonstrate feasibility and therapeutic potential of theranostics in patients with
primary, relapsed or metastasis brain tumors. Further studies preferentially
well-designed multicenter international clinical trial is warranted.
RADI-16. EFFICACY OF WBRT AMONG THE SUB-TYPES OF
METASTATIC BREAST CANCER
Shija Mathew, Udaykrishna A. S., Lokesh V.; Kidwai Memorial Institute
Of Oncology, Bangalore, India
OBJECTIVES: To understand the effect of Whole Brain Radiation
(WBRT) in terms of Age, Neurological performance, Radiological Improvement and the Overall Survival. METHODS: 34 Patients [Median Age:
45 years (31- 65)] with Metastatic Breast Carcinoma who presented with
Brain metastasis to the Department of Radiation Oncology at Kidwai Memorial Institute of Oncology and subjected to Whole Brain Radiotherapy/
Focal RT were taken into the study. The efficacy of WBRT was assessed

RADI-17. OUTCOMES FOR PATIENTS WITH TRIPLE NEGATIVE
BREAST CANCER TREATED WITH UPFRONT STEREOTACTIC
RADIOSURGERY FOR BRAIN METASTASES

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive
subtype with high propensity of developing brain metastases (BM). Clinical
outcomes and prognostic factors after stereotactic radiosurgery (SRS) for BM
were not well defined. METHODS: We identified 57 consecutive TNBC patients (pts) treated with single fraction SRS for BM during 05/2008–04/2018.
Overall survival (OS) from BM diagnosis and freedom from BM progression
(FFBMP) after initial SRS were evaluated. BM progression was defined as local
and/or distant brain failure (LBF, DBF) after SRS. Kaplan-Meier analyses and
Cox proportional hazard regression were used to estimate survival outcomes
and identify prognostic factors. RESULTS: The median time to BM development from TNBC diagnosis was 23.7 months (mo) (range 0.7‒271.1). Median OS was 13.1 mo (95%CI 8.0‒19.5). On univariate analysis, Karnofsky
performance score (KPS) >70 (p=0.03), number of BMs <3 (p=0.016), and
BM among the first metastatic sites (p=0.04) were associated with longer OS.
On multivariate analysis, KPS ≤70 was associated with higher risk of death
(HR 3.0, p=0.03). Of 46 pts with adequate imaging follow-up, 29 (63%) had
intracranial progression with a median FFBMP of 7.4 mo (95% CI 5.7–12.7).
At 12 mo the estimated cumulative DBF rate was 61.1% (95%CI 40.8%–
74.4%) and LBF rate was 17.8% (95%CI 2%–31.1%). Number of BMs (≥3
vs <3) was not associated with FFBMP (p=0.7). Of the 29 pts with BM progression, additional radiation therapy (RT) (vs. no RT) was associated with
improved survival (21.7 vs. 7.0 mo, p<0.0001). CONCLUSIONS: TNBC pts
with BM treated with SRS had an OS of 13.1 mo and FFBMP of 7.4 mo.
Good KPS was an independent prognostic factor for OS. Further studies with
more pts or conducted prospectively are needed to better understand and to
improve treatment outcomes in this pt population.
RADI-18. SURVIVAL AND DISEASE CONTROL AFTER UPFRONT
STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM
BREAST CANCER
Yan Wang1, Ran An1, Fuchenchu Wang2, Chao Gao3,
Akshara Singareeka Raghavendra4, Yon Son Betty Kim5,
Tina Marie Briere6, Diana N. Amaya7, Jing Li1; 1MD Anderson Cancer
Center- University of Texas, Department of Radiation Oncology, Houston,
TX, USA, 2MD Anderson Cancer Center- University of Texas, Department
of Biostatistics, Houston, TX, USA, 3The Fourth Hospital of Hebei
Medical University, Shijiazhuang, China, 4MD Anderson Cancer CenterUniversity of Texas, Department of Breast Medical Oncology, Houston,
TX, USA, 5MD Anderson Cancer Center- University of Texas, Department
of Neurosurgery, Houston, TX, USA, 6MD Anderson Cancer CenterUniversity of Texas, Department of Radiation Physics, Houston, TX,
USA, 7MD Anderson Cancer Center- University of Texas, Department of
Radiation Oncology, Houston, TX, USA
BACKGROUND: As systemic therapy for metastatic breast cancer (BC)
improves, the survival benefit from hormonal and targeted therapy urges
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and laser interstitial thermal therapy (LITT) are viable treatment options,
but direct comparative data is scarce. We reviewed the literature to compare the two treatment strategies. METHODS: PubMed, EMBASE, Scopus,
and Cochrane databases were searched. All studies of patients with RN
from brain metastases treated with bevacizumab or LITT were included.
Treatment outcomes were analyzed using indirect meta-analysis with
random-effect modeling. RESULTS: Among the 18 studies included, 143
patients received bevacizumab and 148 underwent LITT. Both strategies
were equally effective in providing post-treatment symptomatic improvement (P=0.187, I2=54.8%), weaning off steroids (P=0.614, I2=25.5%), and
local lesion control (P=0.5, I2=0%). The mean number of lesions per patient
was not statistically significant among groups (P=0.624). Similarly, mean
T1-contrast-enhancing pre-treatment volumes were not statistically different
(P=0.582). Patterns of radiological responses differed at 6-month followups, with rates of partial regression significantly higher in the bevacizumab
group (P=0.001, I2=88.9%), and stable disease significantly higher in the
LITT group (P=0.002, I2=81.9%). Survival rates were superior in the LITT
cohort, and statistical significance was reached at 18 months (P=0.038,
I2=73.7%). Low rates of adverse events were reported in both groups (14.7%
for bevacizumab and 12.2% for LITT). CONCLUSION: Bevacizumab and
LITT can be safe and effective treatments for RN from brain metastases.
Clinical and radiological outcomes are mostly comparable, but LITT may
relate to superior survival benefits in select patients. Further studies are required to identify the best patient candidates for each treatment group.

